9:19 AM
 | 
Jun 15, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

FibroGen's pamrevlumab improves survival in Phase I/II for pancreatic cancer

FibroGen Inc. (NASDAQ:FGEN) reported additional data from 37 treatment-naïve patients with locally advanced, unresectable pancreatic cancer in an open-label, U.S. Phase I/II trial showing that pamrevlumab (FG-3019) plus gemcitabine and Abraxane nab-paclitaxel significantly increased median survival in patients who had...

Read the full 178 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >